Date: December 08, 2021
Time: 8:00am (PST), 11:00am (EST)
Learn how enrichment of primary dendritic cell (DC) subsets and sustainable DC manufacturing advances DC-based cell therapies. In the last decade, several DC-based vaccination and other pioneering immunotherapeutic treatments have paved the way to a new personalized approach to cancer treatment. DC–based vaccination aims to enhance the immune system’s ability to attack the tumor. However, limitations like low efficacy and low sustainability of the manufacturing process are still a challenge for DC-based therapies. This webinar gives insights on how to tackle these challenges in next-generation DC manufacturing: We will focus on enrichment of primary DC subsets from peripheral blood (blood DCs), possible combination with other immunotherapeutic approaches, and increasing manufacturing sustainability with the CliniMACS Prodigy® Platform.
- Discuss the rationale of blood DC-based vaccination including its advantages and limitations, and possible future optimizations (next-generation DC vaccines).
- Provide an overview on how the CliniMACS Prodigy Platform facilitates the development of more effective DC vaccines.
- Review possible developments of next-generation DC vaccines, such as the combination with immune checkpoint blockades and neoantigens.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.